This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
4 Healthcare Stocks to Buy as the Sector Stages a Comeback
by Abhinab Dasgupta
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
by Zacks Equity Research
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
by Zacks Equity Research
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stock to Buy for January 17th
by Zacks Equity Research
WFC, FHN and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2025.
New Strong Buy Stocks for January 17th
by Zacks Equity Research
RIGL, PFIS, PBPB, ICL and KMX have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2025.
Rigel (RIGL) Upgraded to Buy: Here's Why
by Zacks Equity Research
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks
by Nalak Das
We have picked five small-cap stocks that have strong growth potential for 2025. These are: TZOO, EVER, LIND, RIGL, GHM.
Corcept Submits Application for Another Cushing's Syndrome Drug
by Zacks Equity Research
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
by Nalak Das
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive
by Zacks Equity Research
Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive have been highlighted in this Screen of The Week article.
5 Relative Price Strength Options Available for Investors
by Nilanjan Choudhury
RIGL, SYF, SKYW, ALNT and RSI are five stocks with explosive relative price strength.
Rigel Pharmaceuticals (RIGL) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 6,900% and 35.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -15.65% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 83.78% and 13.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 4.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?